1. Anderson R, Thomas DW. 'Toothache stories': a qualitative investigation of why and how people seek emergency dental care. Community Dent Health. 2003 Jun;20(2):106-11.
  2. Locker D, Grushka M. Prevalence of oral and facial pain and discomfort: preliminary results of a mail survey. Community Dent Oral Epidemiol. 1987 Jun;15(3):169-72.
  3. Nalliah RP, Allareddy V, Elangovan S, et al. Hospital emergency department visits attributed to pulpal and periapical disease in the United States in 2006. J Endod. 2011 Jan;37(1):6-9. doi: 10.1016/j.joen.2010.09.006. Epub 2010 Nov 12.
  4. Byers MR, Suzuki H, Maeda T. Dental neuroplasticity, neuro-pulpal interactions, and nerve regeneration. Microsc Res Tech. 2003 Apr 1;60(5):503-15.
  5. Byers MR. Dynamic plasticity of dental sensory nerve structure and cytochemistry. Arch Oral Biol. 1994;39 Suppl:13S-21S.
  6. Caviedes-Bucheli J, Muñoz HR, Azuero-Holguín MM, et al. Neuropeptides in dental pulp: the silent protagonists. J Endod. 2008 Jul;34(7):773-88. doi: 10.1016/j.joen.2008.03.010.
  7. Hahn CL, Liewehr FR. Relationships between caries bacteria, host responses, and clinical signs and symptoms of pulpitis. J Endod. 2007 Mar;33(3):213-9. Epub 2007 Jan 4. doi: 10.1016/j.joen.2006.11.008.
  8. Hahn CL, Liewehr FR. Innate immune responses of the dental pulp to caries. J Endod. 2007 Jun;33(6):643-51. Epub 2007 Mar 6. doi: 10.1016/j.joen.2007.01.001.
  9. Hahn CL, Liewehr FR. Update on the adaptive immune responses of the dental pulp. J Endod. 2007 Jul;33(7):773-81. Epub 2007 Feb 23. doi: 10.1016/j.joen.2007.01.002.
  10. Kim S. Neurovascular interactions in the dental pulp in health and inflammation. J Endod. 1990 Feb;16(2):48-53. doi: 10.1016/S0099-2399(06)81563-3.
  11. Trowbridge HO. Review of dental pain--histology and physiology. J Endod. 1986 Oct;12(10):445-52. doi: 10.1016/S0099-2399(86)80197-2.
  12. Bergenholtz G. Inflammatory response of the dental pulp to bacterial irritation. J Endod. 1981 Mar;7(3):100-4. doi: 10.1016/S0099-2399(81)80122-7.
  13. Sessle BJ. Recent developments in pain research: central mechanisms of orofacial pain and its control. J Endod. 1986 Oct;12(10):435-44. doi: 10.1016/S0099-2399(86)80196-0.
  14. Ellis A, Bennett DL. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth. 2013 Jul;111(1):26-37. doi: 10.1093/bja/aet128.
  15. Mense S. Sensitization of group IV muscle receptors to bradykinin by 5-hydroxytryptamine and prostaglandin E2. Brain Res. 1981 Nov 23;225(1):95-105.
  16. Hall JM. Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther. 1992 Nov;56(2):131-90.
  17. Sundqvist G, Lerner UH. Bradykinin and thrombin synergistically potentiate interleukin 1 and tumour necrosis factor induced prostanoid biosynthesis in human dental pulp fibroblasts. Cytokine. 1996 Feb;8(2):168-77.
  18. Goodis HE, Bowles WR, Hargreaves KM. Prostaglandin E2 enhances bradykinin-evoked iCGRP release in bovine dental pulp. J Dent Res. 2000 Aug;79(8):1604-7. doi: 10.1177/00220345000790081301.
  19. Woda A. Pain in the trigeminal system: from orofacial nociception to neural network modeling. J Dent Res. 2003 Oct;82(10):764-8. doi: 10.1177/154405910308201001.
  20. Sessle BJ. Recent insights into brainstem mechanisms underlying craniofacial pain. J Dent Educ. 2002 Jan;66(1):108-12.
  21. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem. 2004;73:953-90. doi: 10.1146/annurev.biochem.73.011303.073940.
  22. Lord JA, Waterfield AA, Hughes J, et al. Endogenous opioid peptides: multiple agonists and receptors. Nature 1977;267(5611):495-499. doi:10.1038/267495a0. Accessed May 05, 2017.
  23. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med. 1995 Jun 22;332(25):1685-90. doi: 10.1056/NEJM199506223322506.
  24. Bertolini A, Ferrari A, Ottani A, et al. Paracetamol: new vistas of an old drug. CNS Drug Rev. 2006 Fall-Winter;12(3-4):250-75. doi: 10.1111/j.1527-3458.2006.00250.x.
  25. Caballero FJ, Navarrete CM, Hess S, et al. The acetaminophen-derived bioactive N-acylphenolamine AM404 inhibits NFAT by targeting nuclear regulatory events. Biochem Pharmacol. 2007 Apr 1;73(7):1013-23. Epub 2006 Dec 15. doi: 10.1016/j.bcp.2006.12.001.
  26. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008 Jan;153(2):319-34. Epub 2007 Nov 12. doi: 10.1038/sj.bjp.0707531.
  27. Högestätt ED, Jönsson BA, Ermund A, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem. 2005 Sep 9;280(36):31405-12. Epub 2005 Jun 29. doi: 10.1074/jbc.M501489200.
  28. Sinning C, Watzer B, Coste O, et al. New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5. doi: 10.1021/jm800807k.
  29. Anderson BJ. Paracetamol (Acetaminophen): mechanisms of action. Paediatr Anaesth. 2008 Oct;18(10):915-21. doi: 10.1111/j.1460-9592.2008.02764.x.
  30. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther. 2005 Mar-Apr;12(2):133-41.
  31. Huber MA, Terezhalmy GT. The use of COX-2 inhibitors for acute dental pain: A second look. J Am Dent Assoc. 2006 Apr;137(4):480-7.
  32. Ong KS, Seymour RA, Chen FG, et al. Preoperative ketorolac has a preemptive effect for postoperative third molar surgical pain. Int J Oral Maxillofac Surg. 2004 Dec;33(8):771-6.
  33. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
  34. Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther. 2009 Dec;31(12):2804-18. doi: 10.1016/j.clinthera.2009.12.003.
  35. Terlinden R, Ossig J, Fliegert F, et al. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2007 Jul-Sep;32(3):163-9.
  36. Bandolier. The Oxford League Table of Analgesic Efficacy. 2007. Accessed May 05, 2017.
  37. Cooper SA. The relative efficacy of ibuprofen in dental pain. Compend Contin Educ Dent. 1986 Sep;7(8):578, 580-1, 584-8 passim.
  38. Ong CK, Seymour RA. An evidence-based update of the use of analgesics in dentistry. Periodontol 2000. 2008;46:143-64. doi: 10.1111/j.1600-0757.2008.00225.x.
  39. Ong CK, Lirk P, Tan CH, et al. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007 Mar;5(1):19-34. doi: 10.3121/cmr.2007.698.
  40. Derry C, Derry S, Moore RA, et al. Single dose oral ibuprofen for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD001548. doi: 10.1002/14651858.CD001548.pub2.
  41. Toms L, McQuay HJ, Derry S, et al. Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004602. doi: 10.1002/14651858.CD004602.pub2.
  42. McQuay HJ, Moore RA. An Evidence-based Resource for Pain Relief. New York, NY. Oxford Univeristy Press. 1998.
  43. Aminoshariae A, Kulild JC, Donaldson M, et al. Evidence-based recommendations for analgesic efficacy to treat pain of endodontic origin: A systematic review of randomized controlled trials. J Am Dent Assoc. 2016 Oct;147(10):826-39. doi: 10.1016/j.adaj.2016.05.010. Epub 2016 Jul 28.
  44. Hyllested M, Jones S, Pedersen JL, et al. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br J Anaesth. 2002 Feb;88(2):199-214.
  45. Ong CK, Seymour RA, Lirk P, et al. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg. 2010 Apr 1;110(4):1170-9. doi: 10.1213/ANE.0b013e3181cf9281. Epub 2010 Feb 8.
  46. Elia N, Lysakowski C, Tramèr MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology. 2005 Dec;103(6):1296-304.
  47. Litkowski LJ, Christensen SE, Adamson DN, et al. Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model. Clin Ther. 2005 Apr;27(4):418-29. doi: 10.1016/j.clinthera.2005.04.010.
  48. Derry S, Derry CJ, Moore RA. Single dose oral ibuprofen plus oxycodone for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013 Jun 26;(6):CD010289. doi: 10.1002/14651858.CD010289.pub2.
  49. McClellan K, Scott LJ. Tramadol/paracetamol. Drugs. 2003;63(11):1079-86; discussion 1087-8.
  50. Kleinert R, Lange C, Steup A, et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth Analg. 2008 Dec;107(6):2048-55. doi: 10.1213/ane.0b013e31818881ca.
  51. Ong CK, Lirk P, Seymour RA, et al. The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. Anesth Analg. 2005 Mar;100(3):757-73, table of contents. doi: 10.1213/01.ANE.0000144428.98767.0E.
  52. Minutello JS, Newell DH, Thrash WJ, et al. Evaluation of preoperative diflunisal for postoperative pain following periodontal surgery. J Periodontol. 1988 Jun;59(6):390-3. doi: 10.1902/jop.1988.59.6.390.
  53. Minutello JS, Hewell DH, Thrash WJ, et al. Evaluation of postoperative diflunisal for periodontal surgery pain. Am J Dent. 1991 Feb;4(1):33-6.
  54. Modaresi J, Dianat O, Mozayeni MA. The efficacy comparison of ibuprofen, acetaminophen-codeine, and placebo premedication therapy on the depth of anesthesia during treatment of inflamed teeth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Sep;102(3):399-403. Epub 2006 Jun 27.
  55. Drugs for pain. Treat Guidel Med Lett. 2013 Apr;11(128):31-42; quiz 2 p following 42.
  56. Finniss DG, Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain. 2005 Mar;114(1-2):3-6. Epub 2005 Jan 21. doi: 10.1016/j.pain.2004.12.012.
  57. FDA. FDA Drug Safety Communication: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure. April, 2016. Accessed May 08, 2017.
  58. Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002 Dec 17;137(12):947-54.
  59. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005 Dec;42(6):1364-72. doi: 10.1002/hep.20948.
  60. Nourjah P, Ahmad SR, Karwoski C, et al. Estimates of acetaminophen (Paracetomal)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006 Jun;15(6):398-405. doi: 10.1002/pds.1191.
  61. Bower WA, Johns M, Margolis HS, et al. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007 Nov;102(11):2459-63. Epub 2007 Jun 29. doi: 10.1111/j.1572-0241.2007.01388.x.
  62. Liss G, Rattan S, Lewis JH. Predicting and preventing acute drug-induced liver injury: what's new in 2010? Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1047-61. doi: 10.1517/17425255.2010.503706.
  63. FDA. FDA recommends health care professionals discontinue prescribing and dispensing prescription combination drug products with more than 325 mg of acetaminophen to protect consumers. November, 2016. Accessed May 08, 2017.
  64. FDA. All manufacturers of prescription combination drug products with more than 325 mg of acetaminophen have discontinued marketing. December, 2014. Accessed May 08, 2017.
  65. Liew Z, Ritz B, Rebordosa C, et al. Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatr. 2014 Apr;168(4):313-20. doi: 10.1001/jamapediatrics.2013.4914.
  66. Risser A, Donovan D, Heintzman J, et al. NSAID prescribing precautions. Am Fam Physician. 2009 Dec 15;80(12):1371-8.
  67. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000 Sep;16(3):432-6.
  68. Simon RA. Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24.
  69. Inaba T, Ishikawa S, Miyoshi M, et al. [Present status of gastrointestinal damage due to non-steroidal anti-inflammatory drugs (NSAIDs)]. Nihon Rinsho. 2013 Jun;71(6):1109-15.
  70. Choi KH, Kim AJ, Son IJ, et al. Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. J Korean Med Sci. 2010 Mar;25(3):337-41. doi: 10.3346/jkms.2010.25.3.337. Epub 2010 Feb 17.
  71. Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis. 2007 Aug;11(3):563-75, vi-vii. doi: 10.1016/j.cld.2007.06.004.
  72. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut. 1999 May;44(5):731-5.
  73. Ejaz P, Bhojani K, Joshi VR. NSAIDs and kidney. J Assoc Physicians India. 2004 Aug;52:632-40.
  74. Giovanni G, Giovanni P. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol. 2002 Sep-Oct;15(5):480-8.
  75. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086.
  76. Widener HL, Littman BH. Ibuprofen-induced meningitis in systemic lupus erythematosus. JAMA. 1978 Mar 13;239(11):1062-4.
  77. Rodríguez SC, Olguín AM, Miralles CP, et al. Characteristics of meningitis caused by Ibuprofen: report of 2 cases with recurrent episodes and review of the literature. Medicine (Baltimore). 2006 Jul;85(4):214-20. doi: 10.1097/
  78. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003 Aug 16;327(7411):368. doi: 10.1136/bmj.327.7411.368.
  79. Antonucci R, Zaffanello M, Puxeddu E, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012 May 1;13(4):474-90.
  80. Østensen ME, Skomsvoll JF. Anti-inflammatory pharmacotherapy during pregnancy. Expert Opin Pharmacother. 2004 Mar;5(3):571-80. doi: 10.1517/14656566.5.3.571.
  81. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med. 1991 May 17;90(5A):42S-47S.
  82. Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther. 2007;29 Suppl:2477-97. doi: 10.1016/j.clinthera.2007.12.003.
  83. Pickett FA, Terezhalmy GT. LWW’s Dental drug reference with clinical implications, 2nd edition, editor. Philadelphia: Lippincott Williams & Wilkins; 2010.
  84. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000 Jul 24;160(14):2093-9.
  85. Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001 Jun 1;153(11):1089-93.
  86. Meek IL, Vonkeman HE, Kasemier J, et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013 Mar;69(3):365-71. doi: 10.1007/s00228-012-1370-y. Epub 2012 Aug 14.
  87. Awa K, Satoh H, Hori S, et al. Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. J Clin Pharm Ther. 2012 Aug;37(4):469-74. doi: 10.1111/j.1365-2710.2011.01313.x. Epub 2011 Nov 28.
  88. CDC. Opioid Overdose. April, 2017. Accessed May 08, 2017.
  89. World Health Organization. Information sheet on opioid overdose. November, 2014. Accessed May 08, 2017.
  90. Lalley PM. Opioidergic and dopaminergic modulation of respiration. Respir Physiol Neurobiol. 2008 Dec 10;164(1-2):160-7. doi: 10.1016/j.resp.2008.02.004.
  91. Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012 Jul 12;367(2):146-55. doi: 10.1056/NEJMra1202561.
  92. Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med. 1991 Mar;20(3):246-52.
  93. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003 Jun;4(5):231-56.
  94. Christo PJ. Opioid effectiveness and side effects in chronic pain. Anesthesiol Clin North America. 2003 Dec;21(4):699-713.
  95. Whistler JL. Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2012 Mar 1;121(3):189-204. doi: 10.1016/j.drugalcdep.2011.10.031. Epub 2012 Jan 9.
  96. Matthes HW, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996 Oct 31;383(6603):819-23. doi: 10.1038/383819a0.
  97. Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth. 1998 Jul;81(1):58-68.
  98. Bateman DN, Eddleston M, Sandilands E. Codeine and breastfeeding. Lancet. 2008 Aug 23;372(9639):625; author reply 626. doi: 10.1016/S0140-6736(08)61266-0.
  99. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010 Jan 19;152(2):85-92. doi: 10.7326/0003-4819-152-2-201001190-00006.
  100. Canty SL. Constipation as a side effect of opioids. Oncol Nurs Forum. 1994 May;21(4):739-45.
  101. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006 Aug 19;368(9536):704. doi: 10.1016/S0140-6736(06)69255-6.

Additional Resources

  • No Additional Resources Available